<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290537</url>
  </required_header>
  <id_info>
    <org_study_id>2003-0635</org_study_id>
    <nct_id>NCT00290537</nct_id>
  </id_info>
  <brief_title>Phase II Study of ZD6474 in Advanced NSCLC</brief_title>
  <official_title>A Phase II Study of ZD6474 Alone and With Chemotherapy in Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn how the drug ZD6474 affects the amount&#xD;
      of tumor cell death in the body and the amount of blood that can be supplied to the tumor.&#xD;
      The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the&#xD;
      side effects and response to this treatment will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ZD6474 is a new investigational drug that is thought to block the formation of new blood&#xD;
      vessels. The growth of new blood vessels is called angiogenesis. Angiogenesis is thought to&#xD;
      be essential for the growth of tumors beyond a small size. It is hoped that ZD6474 will limit&#xD;
      new blood vessel growth in the tumor and &quot;starve&quot; the tumor by limiting blood flow to it. The&#xD;
      second part of this study also includes paclitaxel (Taxol) and carboplatin (Paraplatin). Both&#xD;
      paclitaxel and carboplatin are standard chemotherapy drugs that are approved by the FDA for&#xD;
      use in the treatment of lung cancer.&#xD;
&#xD;
      Before beginning treatment on this study, you will have a biopsy of your tumor. The tissue&#xD;
      taken during this biopsy will be compared with the tissue taken after you receive ZD6474. The&#xD;
      tumor samples will be compared to see what effect ZD6474 has had on tumor cell death. During&#xD;
      the biopsy procedure, you will receive either a local or general anesthetic depending on the&#xD;
      location of your tumor and a small piece of tumor will be removed with a large needle.&#xD;
&#xD;
      Before treatment starts, you will have a complete physical exam by a physician. You will have&#xD;
      routine blood (about 4 teaspoons) and urine tests. Women who are able to have children must&#xD;
      have a negative blood pregnancy test. You will have a chest x-ray and a CT or MRI scan, a&#xD;
      functional MRI, a bone scan if your doctor thinks it is necessary, and a brain scan. You will&#xD;
      also have an ECG (test to measure the electrical activity of the heart) and a ECHO scan to&#xD;
      make sure your heart is healthy enough to receive this treatment.&#xD;
&#xD;
      Treatment on this study will be given in 3-week cycles. During the first three cycles (i.e.,&#xD;
      the first 9 weeks) you will take a ZD6474 tablet by mouth each morning on an empty stomach.&#xD;
      While on this study you will receive a physical exam every week. You will also receive weekly&#xD;
      blood tests (about 4 teaspoons) for the first 4 weeks of treatment. After that you will&#xD;
      receive blood tests (about 4 teaspoons) before every 3-week cycle.&#xD;
&#xD;
      After 2 weeks of treatment you will have another biopsy of your tumor, and another functional&#xD;
      MRI. After every 9 weeks of treatment and every 2 cycles thereafter you will have a repeat CT&#xD;
      or MRI to evaluate your tumor. If your disease has responded to ZD6474 or stayed the same,&#xD;
      you will go on to the second part of this study. If your disease has gotten worse or&#xD;
      intolerable side effects occur, you will be taken off this study and your doctor will discuss&#xD;
      treatment options with you.&#xD;
&#xD;
      If you continue on to the second part of this study, you will be randomly assigned (as in the&#xD;
      toss of a coin) to receive either: a) daily ZD6474 alone, or b) paclitaxel and carboplatin&#xD;
      every 3 weeks along with daily ZD6474. You have an equal chance of being assigned to either&#xD;
      group. If you receive paclitaxel, you will receive it as a 3-hour infusion into a vein on the&#xD;
      first day of each treatment cycle. If you receive carboplatin, you will receive it by vein&#xD;
      immediately following the paclitaxel infusion. The carboplatin infusion will take between 15&#xD;
      and 30 minutes. Treatment with either daily ZD6474 or ZD6474 plus paclitaxel and carboplatin&#xD;
      will continue until your diseases worsens or until severe side effects occur.&#xD;
&#xD;
      This is an investigational study. ZD6474 is an investigational drug that has been approved by&#xD;
      the FDA for research use only. A total of up to 120 patients will take part in this study.&#xD;
      All will be enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Accrual was suboptimal and increasing the number of patients was not feasible.&#xD;
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One)</measure>
    <time_frame>Radiologic evaluations performed after weeks 2 and 9 of treatment, then every 2 cycles or as indicated if progressive disease is suspected up to 6 cycles or 18 weeks (1 cycle = 3 weeks).</time_frame>
    <description>Evaluate the response rate in patients receiving monotherapy with ZD6474 compared to ZD6474 plus carboplatin plus paclitaxel. No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfil the recruitment target.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Part One: ZD6474</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part Two A: ZD6474 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second part of study where participants randomized to receive 300 mg of ZD6474 daily (group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second part of study where participants randomized to receive 100 mg of ZD6474 daily plus carboplatin AUC 6.0 IV over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks (group B).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZD6474</intervention_name>
    <description>ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.</description>
    <arm_group_label>Part One: ZD6474</arm_group_label>
    <arm_group_label>Part Two A: ZD6474 300 mg</arm_group_label>
    <arm_group_label>Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel</arm_group_label>
    <other_name>Zactima</other_name>
    <other_name>Vandetanib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel</description>
    <arm_group_label>Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>200 mg/m^2 IV Over 3 Hours On Day 1</description>
    <arm_group_label>Part Two B: ZD6474 100 mg + Carboplatin + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. An informed consent form must be completed before any protocol specific screening.&#xD;
             Patient must consent to a tissue biopsy at study entry and again at the week 3.&#xD;
&#xD;
          2. Patients must have a diagnosis of stage IIIb or stage IV non-small cell lung cancer&#xD;
             (histologically or cytologically proven) and must not be eligible for combined&#xD;
             chemotherapy and radiation therapy.&#xD;
&#xD;
          3. Patients must have at least one site of measureable disease that is amenable to&#xD;
             biopsy. The patient must not have had radiation to this site. Lesion must be at least&#xD;
             20 mm in the longest diameter by spiral CT or 20 mm with conventional techniques&#xD;
             according to RECIST.&#xD;
&#xD;
          4. Eligible patients must have an ECOG performance status of 0-1.&#xD;
&#xD;
          5. Patients must have adequate hepatic, renal, and bone marrow function as defined below:&#xD;
             1) Serum creatinine &lt; 1.5 mg/dL or a calculated creatinine clearance &gt; 60 mL/min 2)·&#xD;
             Total bilirubin &lt; 1.5 x ULN ·3) ALT or AST &lt;/= 2.5 x ULN OR ALT or AST &lt;/= 5.0 x ULN&#xD;
             if related to liver metastases OR Alk Phos &lt;/= 2.5 x ULN ·4) WBC &gt; 3,000/mm**3 ·5) ANC&#xD;
             &gt; 1,500 mm**3 ·6) Platelets &gt; 100,000/mm**3 ·7) Hemoglobin &gt; 10 g/dL ·8) PT/PTT &lt; 1.5&#xD;
             x normal&#xD;
&#xD;
          6. Patients must be &gt;= 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients are excluded if they have received prior chemotherapy for this disease type.&#xD;
&#xD;
          2. Patients with brain metastases are not eligible for this study unless treated at least&#xD;
             4 weeks before entry and stable without steroid treatment for 1 week.&#xD;
&#xD;
          3. Prior radiation therapy allowed to &lt;25% of the bone marrow. Prior radiation to the&#xD;
             whole pelvis is not allowed. Prior radiotherapy must be completed at least 4 weeks&#xD;
             before study enrollment. Patients must have recovered from the acute toxic effects of&#xD;
             the treatment prior to study enrollment.&#xD;
&#xD;
          4. Patients may not have any concomitant uncontrolled medical or psychiatric disorders.&#xD;
&#xD;
          5. Patients must not be pregnant or breast-feeding. All women of childbearing potential&#xD;
             must have a negative pregnancy test. Childbearing potential will be defined as women&#xD;
             who have had menses within the past 12 months, who have not had tubal ligation or&#xD;
             bilateral oophorectomy. There is no specific information available on the effects of&#xD;
             this drug on women who are pregnant or breast-feeding. Therefore these patients are&#xD;
             excluded from this study because of the unknown risks involved. All sexually active&#xD;
             patients must practice adequate contraception for the entire treatment period.&#xD;
&#xD;
          6. Patients must not have undergone minor surgery (e.g., central venous catheter&#xD;
             placement) within 24 hours of treatment with ZD6474. Patients may not have undergone&#xD;
             any major surgery (e.g., laparotomy, thoracotomy, or craniotomy) within four weeks of&#xD;
             enrollment.&#xD;
&#xD;
          7. Patients may not have a history of a bleeding diathesis.&#xD;
&#xD;
          8. Patients must agree not to use herbal remedies or other over-the-counter biologics&#xD;
             (e.g., shark cartilage)&#xD;
&#xD;
          9. Significant cardiac event (including symptomatic heart failure or angina) within 3&#xD;
             months of entry or presence of cardiac disease that in the opinion of the Investigator&#xD;
             increase the risk of ventricular arrythmia.&#xD;
&#xD;
         10. History of clinically significant arrhythmia (multifocal PVCs, bigeminy, trigeminy,&#xD;
             ventricular tachycardia) which is symptomatic or requires treatment (CTC grade 3) or&#xD;
             asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on&#xD;
             medication is not excluded.&#xD;
&#xD;
         11. Presence of left bundle branch block (LBBB).&#xD;
&#xD;
         12. Previous history of QT prolongation as a result from other medication that required&#xD;
             discontinuation of that medication.&#xD;
&#xD;
         13. Congenital long QT syndrome or 1st degree relative with unexplained sudden death under&#xD;
             40 years of age.&#xD;
&#xD;
         14. QTc with Bazett's correction that is unmeasurable, or &gt;/= 480 msec on screening ECG.&#xD;
             If a patient has QTc &gt;/= 480 msec on screening ECG, the screening may be repeated&#xD;
             twice (at least 24 hours apart). The average QTc from the 3 screening ECGs must be &lt;&#xD;
             480 msec in order for the patient to be eligible for the study.&#xD;
&#xD;
         15. Any concomitant medications that may cause QTc prolongation or induce Torsades de&#xD;
             Pointes (see Appendix F) or induce CYP3A4 function (see section 8.2).&#xD;
&#xD;
         16. Potassium level less than 3.5 meq/l; calcium and magnesium level outside normal&#xD;
             limits. Supplementation of electrolytes is permitted.&#xD;
&#xD;
         17. Left ventricular ejection fraction less than 45% measured by echocardiogram for&#xD;
             subjects with previous anthracycline therapy (total dose greater than 450 mg/m2),&#xD;
             significant cardiovascular disease, or chest irradiation&#xD;
&#xD;
         18. History of severe hypersensitivity reaction to drugs formulated with polysorbate 80&#xD;
&#xD;
         19. Any concurrent condition which in the investigator's opinion makes it undesirable for&#xD;
             the subject to participate in the trial or which would jeopardize compliance with the&#xD;
             protocol.&#xD;
&#xD;
         20. Participation in an investigational trial within the past 30 days.&#xD;
&#xD;
         21. Because of DCE-MRI, individuals with the following are excluded: 1) Cardiac pacemakers&#xD;
             or neurostimulators, 2) Metal implants other than those approved as being safe in an&#xD;
             MRI environment, 3) Claustrophobia, 4) Physical characteristics that preclude a MRI&#xD;
             scan&#xD;
&#xD;
         22. Hypertension not controlled by medical therapy (systolic blood pressure greater than&#xD;
             160 mm Hg or diastolic blood pressure greater than 100 mm Hg)&#xD;
&#xD;
         23. Currently active diarrhea that may affect the ability of the patient to absorb the&#xD;
             ZD6474 or tolerate diarrhea.&#xD;
&#xD;
         24. Previous or current malignancies at other sites within the last 5 years, with the&#xD;
             exception of cervical carcinoma in situ and adequately treated basal cell carcinoma or&#xD;
             squamous cell carcinoma of the skin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassiliki Papadimitrakopoulou, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas M.D.Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center website</description>
  </link>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>March 18, 2009</results_first_submitted>
  <results_first_submitted_qc>May 4, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2009</results_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>ZD6474</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: 01/19/2006 through 11/03/2006. All participants recruited at University of Texas (UT) MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Part One: ZD6474</title>
          <description>First part of two part treatment, Part One: three 3-week cycles 300 mg of ZD6474 daily. Second part, Part Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks</description>
        </group>
        <group group_id="P2">
          <title>Part Two: ZD6474 + Carboplatin + Paclitaxel</title>
          <description>Second part of two part treatment, Part One /Two: participants randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin AUC 6.0 intravenous (IV) over 15-30 minutes and paclitaxel 200 mg/m^2 IV over 3 hours on Day 1 every 3 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ZD6474</title>
          <description>Part One: three 3-week cycles 300 mg of ZD6474 daily.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="35" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One)</title>
        <description>Evaluate the response rate in patients receiving monotherapy with ZD6474 compared to ZD6474 plus carboplatin plus paclitaxel. No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfil the recruitment target.</description>
        <time_frame>Radiologic evaluations performed after weeks 2 and 9 of treatment, then every 2 cycles or as indicated if progressive disease is suspected up to 6 cycles or 18 weeks (1 cycle = 3 weeks).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ZD6474</title>
            <description>First part of treatment: three 3-week cycles 300 mg of ZD6474 daily. Second part, patients randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin and paclitaxel every 3 weeks.</description>
          </group>
          <group group_id="O2">
            <title>ZD6474 + Carboplatin + Paclitaxel</title>
            <description>Second part, patients randomized to receive 300 mg of ZD6474 daily, or 100 mg of ZD6474 daily plus carboplatin and paclitaxel every 3 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response Following Treatment With 300 mg ZD6474 Daily (Study Part One)</title>
          <description>Evaluate the response rate in patients receiving monotherapy with ZD6474 compared to ZD6474 plus carboplatin plus paclitaxel. No formal comparisons could be made and no conclusions drawn because of small numbers in the treatment groups; a result of an inability to fulfil the recruitment target.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change/Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inevaluable for Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected through three 3-week cycles, then up to two weeks after treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ZD6474</title>
          <description>Part One: three 3-week cycles 300 mg of ZD6474 daily.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HEMORRHAGE/BLEEDIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>VISION LOW</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>PAIN (EYE)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>INCONTINENCE, ANAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>NAUSEA ALONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>PAIN (ABDOMEN NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>EDEMA: LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT, SGPT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased (AST, SGOT)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, PULMON</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MULTIFORM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>PRURITUS/ITCHING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vali Papadimitrakopoulou, MD / Associate Professor</name_or_title>
      <organization>U.T. M.D. Anderson Cancer Center</organization>
      <phone>713-792-6363</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

